We are live on ! Find out more
CPX

Canaan Partners XI Portfolio holdings

AUM $127M
1-Year Est. Return 217.49%
This Fund
S&P 500
This Quarter Est. Return
+44.2%
1 Year Est. Return
+217.49%
3 Year Est. Return
+1,311.52%
5 Year Est. Return
10 Year Est. Return
AUM
$118M
AUM Growth
+$35.5M
Cap. Flow
-$179K
Cap. Flow %
-0.15%
Top 10 Hldgs %
100%
Holding
3
New
Increased
Reduced
1
Closed

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
RLYB icon
Rallybio
RLYB
+$179K

Sector Composition

Rank Sector Weight
1 Healthcare 89.7%
2 Technology 10.3%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
TYRA icon
1
Tyra Biosciences
TYRA
$1.91B
$104M 87.81%
4,409,991
AEVA
2
Aeva Technologies
AEVA
$1.26B
$12.2M 10.3%
3,697,039
RLYB icon
3
Rallybio
RLYB
$84.6M
$2.24M 1.89%
238,873
-18,591
-7% -$179K

Similar funds

Canaan Partners XI's Q3 2024 Portfolio in Review

As of Q3 2024, Canaan Partners XI held 3 positions worth $118M, up 43% from $82.6M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q3 2024: portfolio turnover was 0%. Canaan Partners XI opened no new positions and made no exits, leaving the 3-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 89% a quarter earlier, followed by Technology.

  • Canaan Partners XI's biggest Q3 2024 reduction was Rallybio, cutting an estimated $179K.
  • Canaan Partners XI's ten largest holdings make up 100% of its $118M portfolio in Q3 2024.
  • Canaan Partners XI opened 0 new positions and closed 0 in Q3 2024.
  • Canaan Partners XI's portfolio value rose 43% quarter-over-quarter to $118M.

Based on Canaan Partners XI's 13F filing for Q3 2024, filed 16 Oct 2024.